These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 18949409

  • 1. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas.
    Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M.
    Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409
    [Abstract] [Full Text] [Related]

  • 2. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.
    Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M.
    Clin Cancer Res; 2001 Aug; 7(8):2277-84. PubMed ID: 11489802
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M.
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [Abstract] [Full Text] [Related]

  • 4. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
    Hao X, Shao Y, Ren X, Liu H, Xu Q, Li H, Zhang P, An X, Ren B.
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H.
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [Abstract] [Full Text] [Related]

  • 6. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 7. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.
    Cancer Res; 2008 May 15; 68(10):3931-40. PubMed ID: 18483279
    [Abstract] [Full Text] [Related]

  • 8. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 9. [Inhibitory effect of dendritic cells pulsed with MAGE-3 peptide on transplanted murine gastric cancer in mice].
    Lü B, Liu BY, Zhang Y, Chen XH, Zhu ZG, Yin HR, Lin YZ.
    Zhonghua Yi Xue Za Zhi; 2005 Aug 10; 85(30):2120-3. PubMed ID: 16313822
    [Abstract] [Full Text] [Related]

  • 10. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H, Yamagishi H.
    Jpn J Clin Oncol; 2007 Feb 10; 37(2):140-5. PubMed ID: 17255158
    [Abstract] [Full Text] [Related]

  • 11. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.
    J Immunother; 2006 Feb 10; 29(5):499-511. PubMed ID: 16971806
    [Abstract] [Full Text] [Related]

  • 12. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Trakatelli M, Toungouz M, Lambermont M, Heenen M, Velu T, Bruyns C.
    Cancer Gene Ther; 2005 Jun 10; 12(6):552-9. PubMed ID: 15665821
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Anticancer Res; 2009 Feb 10; 29(2):647-55. PubMed ID: 19331215
    [Abstract] [Full Text] [Related]

  • 14. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.
    Toungouz M, Libin M, Bulté F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T.
    J Leukoc Biol; 2001 Jun 10; 69(6):937-43. PubMed ID: 11404379
    [Abstract] [Full Text] [Related]

  • 15. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V.
    Clin Cancer Res; 2006 Dec 15; 12(24):7380-8. PubMed ID: 17189411
    [Abstract] [Full Text] [Related]

  • 16. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [Abstract] [Full Text] [Related]

  • 17. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ, Sui YF.
    Oncol Rep; 2008 Jul 01; 20(1):245-52. PubMed ID: 18575744
    [Abstract] [Full Text] [Related]

  • 18. [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
    Iinuma H, Okinaga K, Fukushima R, Inaba T, Iwasaki K, Arai T, Tamura J, Kumagai H.
    Gan To Kagaku Ryoho; 2004 Oct 01; 31(11):1640-2. PubMed ID: 15553669
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, Nagai I, Sato N, Hiratsuka H.
    Cancer Sci; 2011 Feb 01; 102(2):324-9. PubMed ID: 21143701
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cells: tools and targets for antitumor vaccination.
    den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ.
    Expert Rev Vaccines; 2005 Oct 01; 4(5):699-710. PubMed ID: 16221071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.